Phase 3 Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have been receiving regular kidney dialysis (hemodialysis) for at least 3 months
- People who are covered by a social security or health insurance plan
- People who have read, understood, and signed a consent form agreeing to take part
Who may not be able to join:
- People who need to take long-term blood-thinning (anticoagulant) medication for conditions such as an irregular heartbeat, blood clots, mechanical heart valves, or blood clots inside the heart
- People taking two different blood-thinning/anti-clotting medications at the same time, or taking aspirin at a dose higher than 160 mg per day
- People with poorly controlled high blood pressure (above 180/110 mmHg)
- People who had a stroke caused by a blocked blood vessel in the 30 days before joining
- People with a history of a serious, unexplained bleeding episode that required a hospital stay or a blood transfusion, at any point in their life
- People who had surgery in the 30 days before joining
- People with an additional condition that significantly raises their risk of bleeding, such as a known blood clotting disorder, a low platelet count (below 100G/L), an active cancer affecting the digestive or urinary system, or a known abnormal blood vessel in the brain
- People with severe liver disease
- People taking certain strong medications that can interfere with how the body processes the study drug, including rifampin, St. John's Wort, carbamazepine, phenytoin, or phenobarbital
- People who are considered unlikely to follow the trial's requirements as directed
- People who are pregnant or breastfeeding, or people of childbearing age who are not using an effective form of contraception
- People who have a medical condition that makes blood-thinning treatment unsuitable, such as anti-phospholipid antibody syndrome
- People with a known allergy to rivaroxaban or any of its ingredients, including lactose monohydrate
- People who are under legal guardianship or conservatorship
- People who are currently taking part in another clinical study, or who finished another clinical study less than 30 days before joining this one
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Fabrice IVANES, MD-PhD, University Hospital of TOURS
Phone: +33247473663
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pharmacodynamics of 3 reduced dose regimen of rivaroxaban (5 mg/day, 10 mg/day, or 15 mg/day); Pharmacokinetics of 3 reduced dose regimen of rivaroxaban (5 mg/day, 10 mg/day, or 15 mg/day)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.